Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
PLoS One ; 10(4): e0124659, 2015.
Article in English | MEDLINE | ID: mdl-25894562

ABSTRACT

Mucosal-associated invariant T (MAIT) cells are evolutionarily conserved antimicrobial MR1-restricted CD8(+) T cells co-expressing the semi-invariant TCR Vα7.2, and are numerous in the blood and mucosal tissues of humans. MAIT cells appear to undergo exhaustion in chronic viral infections. However, their role in human immunodeficiency virus type 1 (HIV-1) mono-infection and HIV/tuberculosis (TB) co-infection have seldom been elaborately investigated. We conducted a cross-sectional study to investigate the frequencies and phenotypes of CD161(++)CD8(+) T cells among anti-retroviral therapy (ART)/anti-TB therapy (ATT) treatment-naïve HIV/TB co-infected, ART/TB treated HIV/TB co-infected, ART naïve HIV-infected, ART-treated HIV-infected patients, and HIV negative healthy controls (HCs) by flow cytometry. Our data revealed that the frequency of MAIT cells was severely depleted in HIV mono- and HIV/TB co-infections. Further, PD-1 expression on MAIT cells was significantly increased in HIV mono- and HIV-TB co-infected patients. The frequency of MAIT cells did not show any significant increase despite the initiation of ART and/or ATT. Majority of the MAIT cells in HCs showed a significant increase in CCR6 expression as compared to HIV/TB co-infections. No marked difference was seen with expressions of chemokine co-receptor CCR5 and CD103 among the study groups. Decrease of CCR6 expression appears to explain why HIV-infected patients display weakened mucosal immune responses.


Subject(s)
CD8-Positive T-Lymphocytes/cytology , Coinfection/immunology , HIV Infections/immunology , NK Cell Lectin-Like Receptor Subfamily B/metabolism , Programmed Cell Death 1 Receptor/metabolism , Receptors, Antigen, T-Cell/metabolism , Tuberculosis/immunology , Adult , Anti-HIV Agents/pharmacology , Anti-HIV Agents/therapeutic use , Antitubercular Agents/pharmacology , Antitubercular Agents/therapeutic use , CD8-Positive T-Lymphocytes/drug effects , CD8-Positive T-Lymphocytes/metabolism , Cell Count , Coinfection/drug therapy , Cross-Sectional Studies , Female , Gene Expression Regulation/drug effects , HIV Infections/drug therapy , Humans , Male , Phenotype , Receptors, CCR6/metabolism , Tuberculosis/drug therapy
2.
Am J Trop Med Hyg ; 91(6): 1176-8, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25246695

ABSTRACT

The predictors of severe disease or death were determined for 85 melioidosis patients in Kuala Lumpur, Malaysia. Most of the patients were male, > 40 years old, and diabetic. Severe disease or death occurred in 28 (32.9%) cases. Lower lymphocyte counts and positive blood cultures were significant independent predictors of severe disease, but age, presentations with pneumonia, inappropriate empirical antibiotics, or flagellin types of the infecting isolates were not. Knowledge of local predictors of severe disease is useful for clinical management.


Subject(s)
Melioidosis/physiopathology , Adult , Female , Humans , Malaysia/epidemiology , Male , Severity of Illness Index
3.
Pathog Dis ; 70(2): 110-8, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24214523

ABSTRACT

Tuberculosis (TB) and human immunodeficiency virus (HIV) infection interfere and impact the pathogenesis phenomena of each other. Owing to atypical clinical presentations and diagnostic complications, HIV/TB co-infection continues to be a menace for healthcare providers. Although the increased access to highly active antiretroviral therapy (HAART) has led to a reduction in HIV-associated opportunistic infections and mortality, the concurrent management of HIV/TB co-infection remains a challenge owing to adverse effects, complex drug interactions, overlapping toxicities and tuberculosis -associated immune reconstitution inflammatory syndrome. Several hypotheses have been put forward for the exacerbation of tuberculosis by HIV and vice versa supported by immunological studies. Discussion on the mechanisms produced by infectious cofactors with impact on disease pathology could shed light on how to design potential interventions that could decelerate disease progression. With no vaccine for HIV and lack of an effective vaccine for tuberculosis, it is essential to design strategies against HIV-TB co-infection.


Subject(s)
Coinfection/pathology , HIV Infections/complications , HIV Infections/pathology , Tuberculosis/complications , Tuberculosis/pathology , Coinfection/drug therapy , Drug Interactions , Drug-Related Side Effects and Adverse Reactions , HIV Infections/drug therapy , Humans , Immune Reconstitution Inflammatory Syndrome/chemically induced , Tuberculosis/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...